Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
02.09.2008
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment
21.08.2008
Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology
Home
News & Events
Publications
Debio 025
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
01-Apr-2008
Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent
15-Mar-2008
Genetic and Pharmacologic Inhibition of Mitochondrial-dependent Necrosis Atte uates Muscular Dystrophy
11-Mar-2008
The Cyclophilin Inhibitor Debio-025 Shows Potent Anti-Hepatitis C Effect in Patients Coinfected with Hepatitis C and Human Immunodeficiency Virus
25-Jan-2008
In vivo & in vitro effects of Debio 025 in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy
13-Dec-2007
The Role of Cyclophilins and Cyclophilin Inhibitors in the Replication of HCV
23-Nov-2007
The cyclophilin inhibitor Debio 025 is a potent inhibitor of Hepatitis C virus replication in vitro and has unique resistance profile
29-Aug-2007
Cyclophilin inhibitors in Hepatitis C viral Infection
24-Apr-2007
Evaluation of a cyclophilin inhibitor in Hepatitis C virus-infected chimeric mice in vivo
14-Apr-2007
Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of Emerging Viral Resistance
11-Apr-2007
The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for HCV replication in Man
31-Mar-2007
Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV
31-Oct-2006
The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects
27-Oct-2006
Non-immunosuppressive Cyclosporin Debio-025 with Interferon shows synergistic Anti-HCV Effect in Chimeric Mouse
24-Sep-2006
Selective inhibitors of Hepatitis C virus replication
02-Sep-2006
Postconditioning and Debio-025 Prevent LV Remodelling and Reduce Mortaility Following Acute Myocardial Infarction in Mice
30-Aug-2006
Cyclosporine increases Human Immunodeficiency virus Type 1 Vector Transduction of Primary Mouse Cells
01-Jul-2006
In Vivo and in Vitro Effects of Debio-025, a non-immunosuppressive Cyclosporin A Derivative on Duchene Muscular Dystrophy
24-Jun-2006
Hepatoprotection by Cyclosporin A in Experimental Hepatitis. Sorting Desensitization of the Mitochondrial Permeablility Transition Pore from Immunosuppression
21-May-2006
The non-immunosuppressive Cyclosporin A analogue Debio-025 is a potent inhibitor of Hepatitis C virus replication in vitro
25-Apr-2006
Debio-025 is a Promising New Drug for the Treatment of Chronic Hepatitis C
< Prev
1
2
Next >
Results 1 - 20 of 28
Triptorelin / Decapeptyl / Trelstar
( 7 items )
Oxaliplatin – Eloxatin – Elplat
( 12 items )
Debio 9902 - ZT-1
( 8 items )
Debio 8609 Sanvar
( 1 items )
Archives
( 15 items )